Vaxart gets BARDA nod to begin dosing in 10,000-participant portion of phase 2b Covid-19 clinical trial

Join Pharma | Login

	Editorial


	SUPREME COURT’S INTERVENTION NEEDED
	Wednesday, May 14, 2025
	Availability of drugs for rare diseases or orphan diseases at reasonably affordable prices has been a major issue the country, for that matter the entire world, has been facing for a long time now.
	Past Editorial...

TODAY'S NEWS


18:00 [IST]	Vaxart gets BARDA nod to begin dosing in 10,000-participant portion of phase 2b Covid-19 clinical trial
17:00 [IST]	Endo launches Adrenalin ready-to-use premixed bag line with new concentration
16:00 [IST]	Infant with rare, incurable disease is first to successfully receive personalized gene therapy treatment
15:00 [IST]	GE HealthCare introduces CleaRecon DL, a technology powered by a deep-learning algorithm, to improve quality of CBCT images
14:15 [IST]	Hypertension in India: A silent epidemic needs for awareness, diagnosis & control: Experts
14:00 [IST]	Autonomix Medical’s innovative catheter-based platform technology receives US patent

more news >>

TOP NEWS


08:00 [IST]	Import of bulk drugs grows around 2 per cent in FY25
08:00 [IST]	Green-space inclusion in hospital infra a strategic intervention that supports healing & scalability: Arti Gugnani
08:00 [IST]	Academicians in MP see the impending revision of B Pharm syllabus will reshape B Pharm course
08:00 [IST]	Indian cos are expanding their presence in RoW markets due to strong demand, less competition: Nilesh Patel
08:00 [IST]	China pharma advances from ‘imitation to innovation’ to propel global pharma pipelines: Dr Sheryl Ding
08:00 [IST]	DoP invites applications for production of 11 bulk drugs under PLI scheme

more news >>

YESTERDAY'S NEWS


18:00 [IST]	Excision announces publication highlighting EBT-107 for treatment of chronic hepatitis B in bioRxiv
17:15 [IST]	Protecting every breath: Gleneagles Hospital’s ‘Mask Up Mumbai’ drive raises asthma awareness
16:00 [IST]	NIH researchers discover tissue biomarker that may indicate higher risk of aggressive breast cancer development and death
15:40 [IST]	Eye-Q & NTPC drive successful cataract intervention for 100 patients in Surat village
13:45 [IST]	STEERLife redefines potent drug development with clean, green, continuous processing
12:40 [IST]	Kaushik Desai now appointed member of the WHO Expert Committee on ECSSP

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

USFDA Warning Letters Recently Posted For March 2025 USFDA Warning Letters Recently Posted For February 2025 Mephenamic Acid 250mg And Dicyclomine 20mg Tab Triamcinolone 40 Mg/ml Inj. Ondansetron 2mg/ml

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers